Patent Application
20140162320
This invention relates to a vector to be used for introducing a foreign gene by homologous recombination and preparation method of a vector in which a foreign gene has been introduced.
Generally, restriction enzyme is usually used for introduction of desired gene into vector. Specifically, a vector is cleaved with a specific restriction enzyme at multicloning site and a nucleic acid fragment of desired gene having the same restriction enzyme site with such specific restriction enzyme is introduced to such cleaved site. The following method for introduction of a desired gene into vector has been recently developed and is commonly used; preparing a nucleic acid fragment which contains a desired gene having two different sequences at either end of the fragment, each of which is homologous with corresponding sequence existing in vector; and causing homologous recombination between the above two sequences in vector and in nucleic acid fragment. (Zhang Y, Muyrers J. P. P., Testa G and Stewart A. F. DNA cloning by homologous recombination in E. Coli. Nature Biotechnology 18: 1314-1317, 2000, and Quinn Lu, Seamless cloning and gene fusion. TRENDS in Biotechnology 23: 199-207, 2005)
The above method using homologous recombination is very simple, easy-to-use and convenient method in terms of introduced desired genes into a vector without depending on the restriction enzyme sites. However, unexpected homologous recombination is induced at high rates inside the vector other than a certain region, in case that multiple sequences homologous exist in the vector to be introduced foreign gene by homologous recombination. As the result, it is very difficult or almost impossible to obtain the vector into which desired gene is introduced, when introduction of desired gene to such vector is tried using homologous recombination method, because homologous recombination inside the vector frequently occurs. This is shown in a result of experiment mentioned in non-patent literature 1.
Retroviral vectors or lentiviral vector (a kind of retroviral vectors) is one of typical example that two sequences homologous with one another exist in a certain region in the vector other than the region to be intended to introduce foreign gene by homologous recombination. Retroviral vector and lentiviral vector are used for research and therapeutic purposes in various fields because these vectors are possible to introduce significantly a gene into animal cell having a characteristic of difficulty in gene introduction. Retroviral vector and lentiviral vector have long terminal repeat (LTR) being homologous sequence in two regions as shown in
Purpose of this invention is to provide a new vector technology by which the problem of the above conventional technology is solved and foreign genes can be introduced by homologous recombination. In particular, this invention is to provide means that can effectively select a vector in which a foreign gene has been introduced in a method of introducing a foreign gene for a method of introducing a foreign gene into a vector containing multiple sequences homologous with one another at a certain region other than an intended region into which the foreign gene is introduced by homologous recombination.
We, inventors examined in order to solve the above problem intensively. In the method of introducing a foreign gene by homologous recombination into the vector containing multiple sequences homologous with one another in a region where introduction of the foreign gene by homologous recombination is not expected, it was found that the use of a vector containing two sequences homologous with two sequences for introducing foreign genes by homologous recombination and a marker gene which is arranged in an adjacent region located between one side of sequence and another side of sequence for introducing a foreign gene was resulted in effective selection and accession of a vector in which a foreign gene has been introduced. This invention has been accomplished on the basis of the above findings.
That is to say, this invention relates to the followings;
[1] A vector containing a replication origin, sequence A, marker gene X, sequences C and D for introducing a foreign gene by homologous recombination, and sequence B that is homologous with said sequence A, in that order, wherein said sequences C and D are directly or indirectly adjacent, and for use in introducing the foreign gene between said adjacent sequences C and D.
[2] The vector according to [1], wherein the vector is a retroviral vector.
[3] The vector according to [1] or [2], wherein the vector is a lentiviral vector.
[4] The vector according to any one of [1] to [3], wherein said sequence A is 3′LTR of a retroviral genome and said sequence B is 5′ LTR of a retroviral genome.
[5] The vector according to any one of [1] to [3], wherein said sequence A is 5′ LTR contained in a retroviral genome and said sequence B is 3′ LTR contained in a retroviral genome.
[6] The vector according to any one of [1] to [5], wherein marker gene X is a fluorescence protein gene or a drug-resistant gene.
[7] The vector according to any one of [1] to [5], wherein marker gene X is a gene encoding luciferase or β-galactosidase.
[8] The vector according to any one of [1] to [7], wherein the replication origin and sequence A are indirectly adjacent, and marker gene Y different from marker gene X is contained between said adjacent replication origin and sequence A.
[9] The vector according to any one of [1] to [7], wherein the replication origin and sequence B are indirectly adjacent, and marker gene Y different from marker gene X is contained between the said adjacent replication origin and sequence B.
[10] The vector according to [8] or [9], wherein marker gene Y is a fluorescence protein gene or a drug-resistant gene.
[11] The vector according to [8] or [9], wherein marker gene Y is a gene encoding luciferase or β-galactosidase.
[12] The vector according to any one of [1] to [11], wherein the replication origin is a replication origin of an organism selected from Escherichia coli, bacteriophage, Saccharomyces cerevisiae and Schizosaccharomyces pombe.
[13] A method of producing a vector according to any one of [1] to [12] in which a foreign gene has been introduced between said adjacent sequences C and D, comprising the steps of
(1) preparing a vector according to any one of [1] to [12];
(2) preparing a nucleic acid fragment containing sequence C′ that is homologous with said sequence C, a foreign gene, and sequence D′ that is homologous with said sequence D, in that order;
(3) by exposing said vector and said nucleic acid fragment to conditions to cause homologous recombination, generating a vector in which the foreign gene has been introduced between said adjacent sequences C and D, and forming a host that may contain the vector in which the foreign gene has been introduced between said adjacent sequences C and D;
(4) culturing the host obtained in Step (3), and selecting from the culture a host containing the vector in which the foreign gene has been introduced between said adjacent sequences C and D by identifying the expression of marker gene X as an indicator; and
(5) extracting form the host selected in Step (4) the vector in which the foreign gene has been introduced between said adjacent sequences C and D.
[14] The method according to [13], wherein said Step (3) is performed by mixing said vector and said nucleic acid with an enzyme for homologous recombination to obtain a homologous recombination product, and transforming a host with the obtained product.
[15] The method according to [13], wherein said Step (3) is performed by obtaining a gene encoding an enzyme for homologous recombination and a host containing said nucleic acid fragment and said vector, and expressing the gene encoding an enzyme for homologous recombination in the obtained host.
According to this invention, in a method for introducing a foreign gene by homologous recombination to a vector having multiple sequences homologous with one another, a vector in which the foreign gene has been introduced is effectively selected and obtained. Especially, according to this invention, in a method for introducing a foreign gene by homologous recombination to a vector that is a retroviral vector or lentiviral vector, a vector in which the foreign gene has been introduced is effectively selected and obtained.
5′-LTR and 3′-LTR have homologous sequences.
ψ: Sequence necessary packaging of virus genome into virus particle.
ori: Replication origin of DNA. This is indispensable for replication of DNA in Escherichia coli.
A resistant marker: This is necessary for selective growth of Escherichia coli containing plasmid DNA.
(Vector in this Invention)
This invention relates to a vector using for introducing a foreign gene between adjacent 2 sequences C and D below, wherein the vector contains replication origin, sequence A, marker gene X, 2 sequences C and D for introducing the foreign gene by homologous recombination and sequence B homologous with the above sequence A in that order, and the above sequence C and D are directly or indirectly adjacent.
In this invention, “being directly adjacent” means 2 sequences are directly linked each other and other sequence does not exist on the adjacent site of 2 sequences. On the other hand, “being indirectly adjacent” means 2 sequences are linked through any other sequence.
Characteristic of a vector in this invention is to contain replication origin, sequence A, marker gene X, 2 sequences C and D for introducing foreign gene by homologous recombination, in that order.
In this invention, replication origin means an initiation site of replication of nucleic acid which composes a vector in this invention. The replication origin includes that of a bacteriophage, a prokaryote (including bacteria) and eukaryotic organism. In this invention, a vector is preferable to do a replication origin of bacterium and is more preferable to include a replication origin of Escherichia coli. In this invention, a vector is possible to include a replication origin of bacteriophage or yeast (e.g., Saccharomyces cerevisiae, Schizosaccharomyces pombe).
As is described in the above, the vector of this invention has sequence A and sequence B, in its inside, which are homologous with each other. Sequence A and sequence B is a gene sequence existing without a region to be intended to introduce a foreign gene by homologous recombination. As an example of the vector containing such sequences A and B which are homologous with each other, a retroviral vector is included. To further specify, lentiviral vector is an example of retroviral vector.
However, it is not intended to limit these vectors as a vector having sequences A and B homologous with one another. Sequences A and B homologous with one another means sequences possible to cause recombination by homologous recombination described below. The number of base in sequences A and B is not specially restricted; for example, a sequence so as to cause homologous recombination between each other in at least a part of sequences A and B. The number of base necessary for causing homologous recombination varies according to tools (e.g., enzyme for recombination), for example; the number of base can be possible in a range of 2 to 600. Or, the above “homologous with one another” means that sequences A and B have base sequences similar to each other as much as homologous recombination can be caused. The homology of sequences A and B in a range possible to cause homologous recombination is, for example, 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 100%.
Two sequences C and D are sequences which are used for introducing a foreign gene by homologous recombination. Two sequences C and D are homologous with base sequences of nucleic acid fragment 5′ end and 3′ end containing a foreign gene which are material for introducing foreign gene into vector of this invention. The number of base of two sequences C and D varies according to tools (e.g., enzyme for recombination) possible to use for homologous recombination, for example; the number of base is in a range of 2 to 600. However, it is not intended to limit the number of base within this range. In a case that sequence C is homologous with base sequence of the above nucleic acid fragment 5′ end, sequence D is homologous with base sequence of the above nucleic acid 3′ end. On the other hand, in a case sequence C is homologous with sequence of the above nucleic acid fragment 3′ end, sequence D is homologous with base sequence of the above nucleic acid 5′ end. And “homologous” means that sequences C and D are similar to base sequence of the above nucleic acid fragment 5′ end and 3′ end as much as homologous recombination between sequences C and D in this invention and the above nucleic acid fragment can be caused. The homology between sequence C or D and base sequence of the above nucleic acid fragment 5′ end or 3′ end in a range possible to cause homologous recombination is, for example, 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 100%.
The retroviral vectors including the lentiviral vector have two sequences of 5′ LTR and 3′ LTR as shown in
For example, the base sequence of 3′ LTR is as follows;
Therefore, these two sequences are homologous.
Marker gene X is included in a vector of this invention because marker gene X is a marker for identification of a host which expresses a gene containing in a vector of this invention. Actual function and action of marker gene X is described hereinafter. As is described in the above, marker gene X is a gene to provide a marker for identification of a host which expresses gene containing vector of this invention and is not limited in particular as long as it is a gene which can provide a marker having such function. Marker gene X is, for example, fluorescence protein gene, drug-resistant gene, reporter gene, etc.
Fluorescence protein gene is a gene encoding fluorescence protein such as GFP, YFP, CFP, BFP, Venus, DsRed, HcRed, AsRed, ZsGreen, ZsYellow, AmCyan, AcGFP and Kaede.
Drug-resistant genes are various drug-resistant genes such as ampicillin resistant gene, kanamycin/neomycin resistance gene, tetracycline resistant gene and chloramphenicol resistant gene.
Reporter genes include such as luciferase gene and β-galactosidase.
In the vector of this invention, it is also possible that replication origin and sequence A are indirectly adjacent to one another and marker gene Y different from above marker gene X is contained between the above adjacent replication origin and sequence A. The above example of marker gene X is one of example of the above marker gene. Marker gene Y is not a marker which is directly related to function for selection of vector in which a foreign gene has been introduced of vector of this invention by homologous recombination but a marker gene which is originally contained in the above conventional retroviral vector and lentiviral vector. This means coexistence of such marker gene does not exclude in this invention. That is to say, the function of vector of this invention is not interfered even if a gene different from such marker gene exists at the above site.
The important matter with respect to a vector of this invention is that marker gene X is located between sequence A and sequences C and D. Such position makes it possible to selectively sort only a host containing vector where foreign gene is introduced between sequences C and D by homologous recombination. On the other hand, since above marker gene Y exists between replication origin and sequence A, such marker gene Y is contained not only in a vector in which a foreign gene has been introduced between sequences C and D after homologous recombination but also in a host containing a vector not introduced foreign gene because of homologous recombination caused between sequences A and B. Therefore, such marker gene Y is not able to use for the above selective sorting. This point is explained below further in detail.
For example, resistant marker Y in A of
In order to solve the above problem with conventional vector, in the vector of this invention, marker gene X (selective marker X) is arranged between indirectly adjacent the above sequence A and sequence C for introducing foreign gene by homologous recombination (see C and D of
(Preparation Method in this Invention)
This invention furthermore includes the following processes for method to prepare a vector in which a foreign gene has been introduced between the above adjacent sequences C and D, in the above vectors of this invention;
Step (1) for preparation of vectors in this invention,
Step (2) for preparation of nucleic acid containing sequence C′ homologous with sequence C, foreign gene, and sequence D, homologous with the above sequence D, in that order,
Step (3) for production of vector which foreign genes was introduced between the above adjacent sequence C and D and for formation of hosts containing such vector by exposing the above vector and the above nucleic acid fragment of Step (2) under conditions causing homologous recombination,
Step (4) for cultivation of host obtained from Step (3), and selection of a host containing vector in which a foreign gene has been introduced between sequences C and D, what is chosen by expression of marker gene X from culture as index, and
Step (5) for extraction of vector in which a foreign gene has been introduced between sequences C and D from host obtained by Step (3).
In Step (1), the above vector of this invention is prepared. In a vector containing two sequences homologous with one another, sequences for insertion of desired gene between such homologous sequences by homologous recombination and homologous recombination marker gene is inserted to upstream or downstream site of such sequence by genetic engineering method like ligation, etc.
For example, using genetic engineering method, the above vector of this invention can be prepared by insertion of homologous recombination marker gene X into conventional retroviral vector (including the lentiviral vector) between 5′ LTR or 3′ LTR and sequence (sequence C or D) for insertion of foreign gene by homologous recombination, wherein such LTR and sequence are adjacent to each other. In this case, sequences C and D for insertion of foreign gene by homologous recombination may be conventional sequence existing in retroviral vector or be sequence newly introduced into such retroviral vector.
Step (2) is a process for preparation of insert (inset) containing foreign gene to be introduced by homologous recombination into vector of this invention. In this Step (2), nucleic acid fragment containing sequence C′ homologous with sequence C existing in vector of this invention, foreign gene and sequence D′ homologous with sequence D existing in vector of this invention in that order is prepared. Such nucleic acid fragment can be prepared, by use of 1) forward primer containing sequence C′ in 5′ end region and 2) reverse primer containing sequence D′ on 5′ end region, with nucleic acid amplification method such as PCR method using nucleic acid fragment including foreign gene as genetic template.
Step (3) is a process for 1) creation of vector in which a foreign gene has been introduced between adjacent sequences C and D and 2) formation of host containing vector in which such foreign gene has been introduced under conditions causing homologous recombination between vector of this invention and nucleic acid fragment prepared by Step (2). In Step (3), homologous recombination can be performed in vitro and sometimes in vivo.
In case of in vitro, homologous recombination between vector of this invention and the above nucleic acid fragment can be performed, for example, by 1) in vitro mixing of enzyme to cause homologous recombination, vector of this invention and the above nucleic acid fragment and then 2) incubation of such mixture for appropriate time and at appropriate temperature. Enzymes causing homologous recombination include various recombinase, and commercialized products of cloning system using such recombinase include In-Fusion Advantage PCR cloning kit (Clontech Laboratories, Inc.), Gateway system (Invitrogen Japan K.K.). Then, host able to replicate vector of this invention is transformed using reactant of such homologous recombination so as to form the host containing vector in which a foreign gene has been introduced. As the host to be used, it is only necessary to be suitable for replication origin in vector of this invention; for example, Escherichia coli, bacteriophage, yeast (e.g., Saccharomyces cerevisiae, Schizosaccharomyces pombe). As transformation method, various methods in the public domain can be used according to the kind of host.
In case of in vivo alternative to the above in vitro homologous recombination method, Step (3) can be performed by 1) obtaining a) gene encoding enzyme for homologous recombination and b) host containing vector of this invention and nucleic acid fragment prepared in Step (2), and then 2) expressing gene encoding enzyme for the above homologous recombination in the obtained host. For example, foreign gene can be introduced into vector of this invention by 1) transformation of vector of this invention and nucleic acid fragment prepared in Step (2) in host containing gene encoding enzyme for homologous recombination, 2) expression of gene encoding enzyme for homologous recombination in host, and 3) homologous recombination in host. In this case, because of expression of enzyme to cause homologous recombination in a host, the vector of this invention and the above nucleic acid fragment cause homologous recombination by activity of such enzyme in the host, and then a host containing vector in which a foreign gene has been introduced is obtained. As enzyme for homologous recombination, pRedET contained in kit of Red/ET homologous recombination sold by Gene Bridges GmbH is included. A cell introduced this into a host Escherichia coli (DH10B, HS996, Gene Hogs or TOP 10) is used as a competent cell.
GenLantis sells Xi-Clone High Speed Cloning Kit utilizing original property of a host Escherichia coli with respect to homologous recombination without introducing a gene encoding enzyme for homologous recombination.
Step (4) is a process for selection of a host containing vector in which a foreign gene has been introduced between sequences C and D in vector of this invention by 1) cultivating the host (transformant) obtained in Step (3) and 2) selecting a host expressing a marker gene X from culture. In case that a marker gene is fluorescence protein gene, a host expressing such fluorescence protein can be selected by fluorescence detection. In case that a marker gene X is drug-resistant gene, only a host expressing drug-resistant gene (marker gene X) can be selected if the host (transformant) obtained from medium containing corresponding drug in Step (3) is cultivated. For example, in case that Escherichia coli is used as a host and ampicillin-resistant gene is used as a marker gene X, only Escherichia coli expressing ampicillin-resistant gene can be selected by cultivating Escherichia coli transformant obtained on a plate medium containing ampicillin in Step (3).
As is described in the above, a by-product produced by causing homologous recombination between sequence A and sequence B homologous with one another in vector of this invention is supposed 1) to contain a replication origin and not to contain a marker gene X and 2) to contain a marker gene X and not to contain a replication origin. The by-product which contains a marker gene X and does not contain a replication origin is not replicated in the host because of lack of a replication origin. On the other hand, with respect to a by-product which contains a replication origin and does not contain a marker gene X, marker gene X is not expressed in the host. For example, in case that Escherichia coli is used as a host and ampicillin-resistant gene is used as a marker gene X, if Escherichia coli transformant obtained in Step (3) is cultivated on a plate medium containing ampicillin, Escherichia coli introduced a by-product containing ampicillin-resistant gene (marker gene X) and not containing a replication origin has such by-product lacking the replication origin, and such by-product is not replicated in Escherichia coli host and ampicillin-resistant gene is not expressed. Therefore, Escherichia coli introduced a by-product containing ampicillin-resistant gene (marker gene X) and not containing the replication origin is not able to grow on a plate medium containing ampicillin and to form colony. On the other hand, Escherichia coli introduced by-product containing a replication origin and not containing ampicillin-resistant gene (marker gene X) has such by-product containing replication origin, and such by-product is possible to be replicated in Escherichia coli host and ampicillin-resistant gene is not expressed in such Escherichia coli host. Therefore, Escherichia coli introduced a by-product containing a replication origin and not containing ampicillin-resistant gene (marker gene X) is not able to grow on a plate medium containing ampicillin and to form colony. In this way by this invention, the host introduced the above by-product is excluded basing on expression or non-expression of marker gene X as the index, and as the result, it is possible to efficiently select a host containing a vector in which a foreign gene has been introduced by homologous recombination in a vector of this invention.
Step (5) is a process to extract a vector in which a foreign gene has been introduced between sequences C and D in vector of this invention, from the host selected in Step (4).
As a method for extraction of a vector in which a foreign gene has been introduced between sequences C and D in a vector of this invention, various publicly known nucleic acid extraction technology are included. For example, in case that the host is Escherichia coli, it is possible to extract a vector in which a foreign gene has been introduced between sequences C and D in a vector of this invention, from Escherichia coli host by various publicly known plasmid extraction method.
This invention is specifically explained by showing examples in the followings, but this invention is not limited to the following examples.
An antibody gene is intended to be introduced into a conventional retroviral vector pMX_G (
pMx_G: Vector for expression of antibody H chain
Amp: Ampicillin-resistant gene
hγ: Antibody heavy chain constant region cDNA
SacB: Bacillus subtilis genomic DNA
MCS: Multi-cloning site
NruI, NotI, SalI: Restriction enzyme sites
At first, as shown in
pMx_G: Vector for antibody heavy chain expression
Amp. Ampicillin-resistant gene
hγ: Antibody heavy chain constant region cDNA
SacB: Bacillus subtilis genome derived DNA
SalI, NruI, NotI: Restriction enzyme sites
Detail of each procedure is explained below.
<Introducing Human Antibody Heavy Chain Gene into Retroviral Vector by Homologous Recombination>
Two μg of vectors was cut at 37° C. for 2 hours using NruI restriction enzyme (10 U) (Roche Diagnostic K.K.) under existence of Buffer B (Roche Diagnostic K.K.) in 50 μL of reaction solution and was linearized. After treatment with restriction enzyme, 1 μL of the reaction solution was electrophoresed with 0.6% of agarose gel at 100V for 20 minutes and vector 6 kb and SavB 1.9 kb bands were confirmed. Remaining 49 μL of reaction solution was purified with QIAquick PCR Purification kit (Qiagen N.V.) and was eluted with 30 μL of EB solution attached to the kit.
Sequence possible to insert by homologous recombination into a vector is added to an insert DNA to be introduced into the vector, by amplification of a desired insert (antibody heavy chain) with PCR using 1) a forward primer containing 20 bases homologous with multi-cloning site (MCS) of 5′ upstream of NruI site on 5′ side of vector and 2) a reverse primer containing homologous 20 bases at heavy chain constant region of NruI site of 3′ downstream on 3′ side of vector. (
[Gene Introduction (Gene Bridges GmbH) to Escherichia coli]
One μL of vector and 1 μL of insert DNA were mixed in 1.5 mL of microtube, and 50 μL of Escherichia coli competent cells (Gene Bridges GmbH) for homologous recombination was further added and mixed on ice, and then the mixture was allowed to stand on ice for 15 minutes. After heat-shock for 30 seconds at 42° C., the mixture was further allowed to stand on ice for 5 minutes. And then, after the microtube was incubated for 1 hour at 37° C., the solution in the microtube was plated to LB (Luria-Bertani) agar medium (10 cm dish) containing 100 m/mL ampicillin, 2% sucrose (Nacalai Tesque, Inc.). Standing culture of this plate was performed for 14 hours at 37° C. The composition of used LB agar medium was as follows;
1% polypeptone (Wako Pure Chemical Industries, Ltd.)
0.5% dried yeast extract (Nacalai Tesque, Inc.)
1% sodium chloride (Wako Pure Chemical Industries, Ltd.)
1% agar powder (Nacalai Tesque, Inc.)
*The following reagents were contained in selection medium.
2% sucrose (Nacalai Tesque, Inc.)
100 μg/mL ampicillin (Wako Pure Chemical Industries, Ltd.)
[Homologous Recombination and Introducing Gene into Escherichia coli with the Use of In-Fusion Advantage PCR Cloning Kit (Clontech Laboratories, Inc.: Takara Bio Inc.)]
5 μL of PCR insert and 2 μL of Cloning Enhancer attached to the kit were mixed in 1.5 mL of microtube. After incubation for 15 minutes at 37° C., the mixture was incubated for 15 minute at 80° C. and was allowed to stand on ice. 7 μL of linearized vector and 1 μL of the above PCR insert were mixed with 1 μL of In-fusion enzyme and 2 μL of 5×In-fusion reaction buffer attached to the kit in 1.5 mL of microtube. After incubation for 15 minutes at 37° C., the mixture was incubated for 15 minute at 50° C. and was allowed to stand on ice. Thereafter, TE buffer was added so as to be 50 μL in total volume. 2.54 of this mixture and 50 μL of Escherichia coli (DH5α) competent cells were added and mixed in 1.5 μL of microtube, and were allowed to stand for 15 minutes on ice. After heat shock for 30 seconds at 42° C., the mixture was allowed to stand for another 5 minutes on ice. And then, after the microtube was incubated for 1 hour at 37° C., the solution in the microtube was plated with 100 μg/mL ampicillin, LB (Luria-Bertani) agar medium (a 10 cm dish) containing 2% sucrose (Nacalai Tesque, Inc.). Standing culture of this plate was performed for 14 hours at 37° C.
Composition of the used LB agar medium was as follows;
1% polypeptone (Wako Pure Chemical Industries, Ltd.)
0.5% dried yeast extract (Nacalai Tesque, Inc.)
1% sodium chloride (Wako Pure Chemical Industries, Ltd.)
1% agar powder (Nacalai Tesque, Inc.)
*The following reagents were contained in selection medium.
2% sucrose (Nacalai Tesque, Inc.)
100 μg/mL ampicillin (Wako Pure Chemical Industries, Ltd.)
[Culture of Escherichia coli from Escherichia coli Single Colony]
7-9 colonies of Escherichia coli were picked up and shaking culture of each colony was performed for 14 hours at 37° C. in 2 mL of liquid LB medium containing 100 μg/mL ampicillin.
Plasmid DNA was extracted using QIAprep Miniprep kit (Qiagen N.V.) from the above Escherichia coli and was eluted using 504 of the attached EB solution.
0.2 μg of vector was received restriction enzyme treatment for 2 hours at 37° C. by SalI (15 IU) (Nippon Gene Co., Ltd) in the presence of Buffer H (Nippon Gene Co., Ltd.) in reaction liquid (total volume: 10.14). Thereafter, the reaction solution (10 μL) was electrophoresed for 20 minutes at 100V with 0.6% of agarose gels.
Two bands of desired gene (about 1 kbp from vector) should be observed at about 1 kbp from vector like right-side of
[Introducing Mouse T-Cell Receptor (TCR) α-Chain into a Vector of this Invention by Homologous Recombination: In Case of Selection by Ampicillin Alone and Kanamaycin Alone]
Retroviral vector pMX-KmAm2-ma for homologous recombination shown in left side of
pMx-KmAm2-mTCRα: Vector for expressing TCRα chain
pMx-KmAm2-mTCRβ: Vector for expressing TCRβ chain
Neo/kan: neomycin/kanamycin-resistance gene
Amp. Ampicillin-resistant gene
mTCR Cα: TCR α-chain constant region cDNA
mTCR Cβ: TCR β-chain constant region cDNA
SacB: Bacillus subtilis genome derived DNA
SalI, NruI: Restriction enzyme sites.
In retroviral vector pMX-KmAm2-ma for homologous recombination, a gene corresponding to resistant marker Y (marker gene Y) in the vector shown in
At first, as shown in
pMx-KmAm2-mTCRα: Vector for expressing TCRα chain
pMx-KmAm2-mTCRβ: Vector for expressing TCRβ chain
Neo/kan: Neomycin/kanamycin-resistance gene
Amp: Ampicillin-resistant gene
mTCR Cα: TCRα chain constant region cDNA
mTCR Cβ: TCRβ chain constant region cDNA
SacB: Bacillus subtilis genomic DNA
Escherichia coli is not able to survive in sucrose medium in case of existence of this gene.
Detail of each protocol is explained below.
Two μg of vector was cut for 2 hours at 37° C. in 50 μL of reaction solution in the presence of Buffer B (Roche Diagnostic K.K.) using NruI restriction enzyme (10 U) (Roche) and was linearized. Upon restriction enzyme treatment, 1 μL of reaction solution was electrophoresed with 0.6% of agarose gels for 20 minutes at 100V and bands of vector 6 kb and SacB 1.9 kb were confirmed. Remaining 49 μL was purified with QI Aquick PCR Purification kit (Qiagen N.V.) and was eluted with 30 μL of EB solution attached to the kit.
Insertable sequence is added into an insert DNA to be introduced to a vector by amplification of a desired insert (TCR) by PCR using 1) a forward primer containing sequence of 20 bases homologous with multi-cloning site (MCS) of 5′ upstream at NruI site of vector 5′ side and 2) a reverse primer containing sequence of 20 bases homologous with TCR constant region of 3′ downstream at NruI site of vector 3′ side (
[Gene Introduction into Escherichia coli (Gene Bridges GmbH)]
One μL of a vector and 1 μL of an insert DNA was mixed in 1.5 mL of microtube, and 50 μL of Escherichia coli competent cell for homologous recombination was further added into and mixed in the microtube on ice. The microtube was allowed to stand on ice for 15 minutes. After heat shock for 30 seconds at 42° C., the microtube was further allowed to stand for 5 minutes on ice. Thereafter, the microtube was incubated for 1 hour at 37° C. and then the solution in the microtube was plated to 1) LB (Luria-Bertani) agar medium (10 cm dish) containing 100 μg/mL ampicillin and 2% sucrose (Nacalai Tesque, Inc.) or 2) LB agar medium containing 50 μg/mL kanamycin and 2% sucrose. Standing culture of this plate was performed for 14 hours at 37° C.
The composition of the used LB agar medium was as follows;
1% polypeptone (Wako Pure Chemical Industries, Ltd.)
0.5% dried yeast extract (Nacalai Tesque, Inc.)
1% sodium chloride (Wako Pure Chemical Industries, Ltd.)
1% agar powder (Nacalai Tesque, Inc.)
* The following reagents are contained as a medium for selection.
2% sucrose (Nacalai Tesque, Inc.)
100 μg/mL ampicillin (Wako Pure Chemical Industries, Ltd.) or 50 μg/mL kanamycin sulfate injection (Meiji Seika Pharma Co., Ltd.)
[Culture of Escherichia coli from Escherichia coli Single Colony]
Twelve colonies of Escherichia coli were picked up and shaking culture of each colony was performed for 14 hours at 37° C. in 2 mL of liquid LB medium containing 100 μg/mL ampicillin or 50 μg/mL kanamycin.
Plasmid DNA was extracted from the above Escherichia coli using QIAprep Miniprep kit (Qiagen N.V.) and was eluted using 50 μL of the attached EB solution.
Restriction enzyme treatment of 0.2 μg of vector with SalI (15U) (Nippon Gene Co., Ltd.) was performed for 2 hours at 37° C. in 10.1 μL (total volume) of reaction solution in the presence of Buffer H (Nippon Gene Co., Ltd.). Thereafter, the reaction solution (10 μL) was electrophoresed with 0.6% agarose gel for 20 minutes at 100V, and a vector band 4.5 kb and a desired DNA OT1 TCRα+Amp band 1.9 kb were confirmed (
As the other example of vector in this invention, 2 kinds of vectors shown in
In pMx-KmAmSEP-mTCRα shown in the right of
Neo/kan: Neomycin/kanamycin-resistance gene
Amp: Ampicillin-resistant gene
mTCR Cα: TCRα chain constant region cDNA
mTCR Cβ: TCRβ chain constant region cDNA
SacB: Bacillus subtilis genome derived DNA
Cloning of a desired DNA was performed actually using a vector of this invention for insertion of a desired DNA fragment by homologous recombination method. The detailed procedure was as follows;
Human T lymphocyte was sorted by a cell sorter so as to be one cell in each well of 96well PCR plate.
TCR Vα region and TCR Vβ region were amplified by 5′-RACE method from near site of constant region 5′ of TCR to upstream of TCR V gene. The amplified TCR Vα region and TCR Vβ region were incorporated using homologous recombination system of Gene Bridges GmbH or Clontech Laboratories, Inc. into an expression vector for homologous recombination; pMX-KmAm2-hTCRα, pMX-KmAm2-hTCRβ [vector where ampicillin-resistant gene of pMX vector which is a publicly known retroviral vector is substituted to kanamycin-resistant gene by genetic engineering method in advance and sequences (MCS, NruI, SacB, NruI, a part of human TCR gene constant region) for insertion are inserted.].
A vector obtained by conventional method was introduced into Escherichia coli and Escherichia coli resistant both to ampicillin and kanamycin were cultured overnight on agar medium, and the expressed colonies were picked up one by one and were cultured in LB medium containing 2 mL of ampicillin and kanamycin. On the next day, plasmid DNA was purified, was cut with both restriction enzymes BamHI and NolI and was analyzed with agarose gel.
As the result, an intended band was detected with respect to 21 out of 24 plasmid DNA as shown in the following
Then, when the sequence of insert of plasmid DNA was analyzed, a functional TCR gene was confirmed to be inserted into the expression vector in frame as shown in
The obtained TCRα chain and TCRβ chain genes were simultaneously introduced into mouse T cell strain TG40 which does not express endogenous TCR gene, and the expression of mouse CD3 molecule to cellular surface was analyzed. As the result, expression of CD3 molecule to cellular surface was confirmed by flow cytometry analysis (
| Number | Date | Country | Kind |
|---|---|---|---|
| 2011-075273 | Mar 2011 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2012/057875 | 3/27/2012 | WO | 00 | 9/30/2013 |
